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APOBEC3B (A3B) is a DNA cytosine deaminase and catalyzes cytosine deamination, resulting in muta-
tions in genomic DNA. A3B is aberrantly expressed in a variety of cancers and considered to be a source of
genomic mutations that contribute to cancer progression and metastasis. However, the mechanisms
through which A3B expression is dysregulated in cancer cells are not fully elucidated. Here we report
that the classical NF-kB pathway plays a crucial role in the transcriptional regulation of A3B in various
cancer cells, including lymphoid malignancies. PMA, a strong activator of PKC, induces A3B at both mRNA
and protein levels in cancer cell lines, and speciﬁc inhibitors of both PKC and IKK downregulate A3B
expression. Using luciferase reporter and EMSA assays, we identify 3 NF-kВ binding sites in the A3B
promoter and reveal that NF-kB p65/p50 and p65/c-Rel heterodimers are important for A3B transcrip-
tion. These results suggest that the classical NF-kB pathway is responsible for activation of A3B mRNA
expression and further imply that inhibition of PKC and IKK might augment cancer treatment by
reducing cancer progression and metastasis through downregulation of A3B expression.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
APOBEC3B (A3B) is a DNA cytosine deaminase that has emerged
as an intrinsic mutagen. Recent studies using next generation
sequencing deﬁned the A3B-mediated genomic DNA mutation
signature found in various cancer types including breast, esopha-
geal, head and neck, uterus, ovarian cancers as well as hematologic
malignancies [1,2]. Various cancers aberrantly express A3B and
accumulate context-speciﬁc genomic DNA mutations [3,4]. We
have previously demonstrated that A3B induces somatic mutations
in the human genome [5]. Others showed that overexpression of
A3B is correlated to aggressive phenotypic markers in breast cancer
[6,7] and poor outcome in lung cancer [8]. These studies suggest
that A3B-mediated mutations contribute to disease progression
and cancer metastasis.
Recent studies demonstrated that two transcriptionallogy & Oncology, Graduate
ahara-cho, Sakyo-ku, Kyoto,
akaori-Kondo).
Inc. This is an open access article uregulators, MAF and ZNF384, are involved in A3B transcription [2,9].
However, MAF-overexpression accounts for a small part of multiple
myeloma cases [10] and HPV causes a limited type of cancers such
as cervical and oropharyngeal cancer, suggesting that other
signaling pathways are more likely to be involved in aberrant A3B
expression throughout a broad range of cancer types.
The nuclear factor-kappa B (NF-kB) transcription factor plays a
pivotal role in the regulation of immune responses and inﬂam-
mation [11,12] and the aberrant activation of NF-kB pathway results
in oncogenesis and cancer progression [13,14]. A variety of stimuli
such as virus infection, activation of kinases and oncogenes, over-
production of cytokines, and dysregulation of cell surface receptors,
activate the NF-kB pathway. NF-kB protein family, including RelA
(p65), Rel (c-Rel), RelB, NF-kB1 (p50), and NF-kB2 (p52), possesses a
conserved Rel homology domain that is responsible for dimeriza-
tion, nuclear localization and DNA-binding [14]. NF-kB pathway is
activated through two distinct signaling pathways: the classical
pathway and the alternative pathway. In the classical pathway,
degradation of IkBa by IKKb activation triggers the translocation of
various heterodimers, predominantly p65/p50, to the nucleus. On
the other hand, in the alternative pathway, IKKa activation leads to
p100 processing and translocation of RelB/p52 into the nucleus.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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kB pathway in human hepatocytes [15]. A recent report demon-
strated that activation of protein kinase C (PKC) by phorbol 12-
myristate 13-acetate (PMA) increased A3B expression through
alternative NF-kB pathway in a normal breast epithelial cell line,
MCF-10A, and that A3B expression was downregulated by shRNA-
mediated depletion of PKCa and PKC inhibitor, concluding that
the PKC/NF-kB pathway regulates A3B expression through the
alternative NF-kB pathway in breast cancer cells [16].
Here we demonstrate that A3B is aberrantly expressed in
various cancer cell lines and PMA induces A3B upregulation in
these cells. Using several chemical inhibitors, we show that the
PKC/NF-kB pathway is involved in the transcriptional regulation of
A3B. EMSA assays further revealed that PMA stimulation enhanced
p65/p50 and p65/c-Rel heterodimers binding to A3B promoter re-
gion. Moreover, shRNA-mediated depletion of p65 suppresses A3B
expression in lymphoma cell lines. These results indicate that the
classical NF-kB pathway plays a crucial role in A3B expression.
2. Material and methods
2.1. Cell culture
HeLa and MCF-7 cells were maintained in DMEM (Nacalai)
containing 10% FBS and 1% penicillin-streptomycin and glutamine
(PSG) (Invitrogen). Jurkat, KIS-1, Granta519, FL18, CEM and ED-
40515 cells were maintained in RPMI1640 containing 10% FBS and
1% PSG.
2.2. Plasmid
DNA fragments corresponding to A3B promoter region from
nucleotides 975 to þ44, numbering relative to the transcription
start site (TSS), were ampliﬁed from genomic DNA of KIS-1 cell lines
with a forward primer (50-NNNNGGTACCCACTGG-
GAGTCCGCTTTGTG-30) and a reverse primer (50-NNNNCTCGAGTA-
GATACGCTTGTCCCTGTC-30). The PCR products were digested by
Kpn I and Xho I and linked into the vector pGL3-basic (Promega).
Reporter plasmids 500, -235, -150, and 50 were generated by
using the 975 to þ44 fragment of the A3B promoter region as
template. A series of 50 primers were designed by Kpn I to link into
vector pGL3-basic (50-NNNNGGTACCACACCTAAGCCTTCCCTTG-30
for construct 500; 50-NNNNGGTACCGCCCAGGACAGATAAAGAC-30
for construct 235; 50-NNNNGGTACCAGCCAGAGCCAGAGAAAC-30
for construct 150; 50-NNNNGGTACCTTTAAGGAGGGCTGTCCAAC-
30 for construct 50). A site-directed mutagenesis construct was
achieved by using KOD -Plus-mutagenesis kit (Toyobo) according to
the manufacturer's instruction; primers used for site-directed
mutagenesis were as follows; kB1 mutant (K1mut) 50-
GCCTGTCTTTATTaaAGGTTCCTCTGCCAG-30 and 50-CTGGCA-
GAGGAACCTttAATAAAGACAGGC-30, kB2 mutant (K2mut) 50-
CGGGAAGGGTCCGaaGAAAACCAGAGCCAG-30, and 50-
CTGGCTCTGGTTTTCttCGGACCCTTCCCG-30, kB3 mutant (K3mut) 50-
GAAGCACCCCGaaGCCTCCCACACCAATG-30, and 50-CATTGGTGTGG-
GAGGCttCGGGGTGCTTC-30, kB4 mutant (K4mut) 50-GGTCACTT-
TAAGGAGaaCTGTCCAACTGC-30 and 50-
GCAGTTGGACAGttCTCCTTAAAGTGACC-30.
2.3. Quantitative RT-PCR
Complementary DNA was synthesized using Primescript II 1st
strand cDNA synthesis kit (Takara). Real-time PCR was performed
with Sybr premix Ex Taq II (Takara) according to manufacturer's
protocol. Target cDNAs were normalized to the endogenous
expression level of a housekeeping reference gene, hypoxanthine-guanine phosphoribosyl transferase 1 (HRPT1). Primers for quan-
titative PCR were as previously described [17]. HPRT1: 50-
TGACCTTGATTTATTTTGCATACC-30 and 50-CGAGCAA-
GACGTTCAGTCCT-30, A3B: 50-GACCCTTTGGTCCTTCGAC-30 and 50-
GCACAGCCCCAGGAGAAG-30.
2.4. Luciferase reporter assay
1.5  105 HeLa cells were transfected with 0.5 mg of promoter
construct using X-tremegene HP DNA transfection reagent (Roche)
according to manufacturer's instruction. Twenty-four hours later,
the transfected cells were treated for 12 h with PMA (1 ng/mL).
Promoter activity was measured with Luciferase Reporter Assay
System (Promega) and was determined by normalization of protein
concentration.
2.5. Immunoblotting
Whole cell lysates were prepared using Direct lysis buffer
(100 mM Tris-HCl [pH 7.5], 2% SDS and 8% Glycerol) supplemented
with protease inhibitor cocktail (Nacalai). Nuclear and cytoplasmic
extracts were prepared as previously described [18]. Antibodies
used for the immunoblotting were polyclonal anti-histone H3
antibody (Millipore) and anti-tubulin antibody MMS-489R (Cova-
nce). Anti-A3B serumwas generated from a rabbit immunized with
C-terminal peptide EEHSQALSGRLRAILQNQGN by Sigma Aldrich.
2.6. Electrophoretic mobility shift assay (EMSA) for NF-kB activity
EMSA was performed using dioxigenin-11-ddUTP labeled oli-
gonucleotides (The DIG gel shift kit, 2nd generation, Roche) ac-
cording to the manufacturer's instruction. Nuclear extracts were
prepared from HeLa cells. The sequences of the oligonucleotide
probes corresponding to kB sites of A3B promoter were kB1 50-
TTTATTGGAGGTTCCTCTGCC-30, kB2 50-GGTCCGGGGAAAACCA-
GAGCCA-30, kB3 50-ACCCCGGGGCCTCCCACACCA-30 and kB4 50-
TAAGGAGGGCTGTCCAACTGC-3’. To perform competition assays,
100-fold excess of unlabeled speciﬁc competitor or non-speciﬁc
competitor (AP1 50-CGCTTGATGAGTCAGCCGGAA-30) oligonucleo-
tides was added to binding reaction mixture. For antibody super-
shift assays, the lysates were preincubated for 10 min at 25 C with
4 mg of antibody before the addition of DIG-labeled oligonucleo-
tides. Antibodies used for the supershift assay were anti-p50
(Abcam, ab7549), anti-p52 (Santa Cruz, sc-7386X), anti-c-Rel
(Santa Cruz, sc-71) and anti-p65 (Santa Cruz, sc-8008X).
3. Results
3.1. PMA upregulates A3B expression at both mRNA and protein
levels
We ﬁrst measured A3B mRNA expression levels in various can-
cer cell lines using quantitative PCR. Several cells showed higher
A3B expression than PBMC, and KIS-1 cells showed the highest
(Fig. 1A). We next examined A3B protein levels in nuclear lysates
from these cell lines using anti-A3B serum developed by immu-
nizing rabbits with A3B C-terminal peptide. We detected A3B
protein at different levels in all four lymphoid malignancy cell lines
(Fig. 1B): Granta 519, originated from mantle cell lymphoma; FL18,
follicular lymphoma; CEM, acute T lymphoblastic leukemia;
ED401515, adult T-cell leukemia. We chose HeLa and Jurkat cells,
which show relatively low A3B expression levels, to test A3B in-
duction upon PMA and other cytokine stimulation. A3B transcripts
were measured by quantitative PCR after 6hr treatment with PMA
(100 ng/mL), TNFa (10 ng/mL), IFNa (1000 U/mL) and DMSO
Fig. 1. PMA induces A3B expression in cancer cell lines. (A) A3B mRNA expression
levels in cell lines were measured by quantitative PCR and normalized to HPRT
expression. A3B mRNA level in PBMC is set as 1. Bar graphs indicate mean ± S.D. (B)
Nuclear lysates were extracted from cell lines and subjected to immunoblotting using
anti-A3B serum. Histone H3 was used as control. (C) HeLa cells (left panel) and Jurkat
cells (right panel) were stimulated with 100 ng/mL PMA, 10 ng/mL TNFa and 1000 U/
mL IFNa for 6 h. A3B mRNA expression levels were measured by qPCR and normalized
to untreated control. Bar graphs indicate mean ± S.D. (D) Cells were treated with 10 ng/
mL PMA for 48 h and nuclear lysates were subjected to immunoblotting using anti-A3B
serum. Fig. 2. PKC inhibitor downregulates A3B expression at both mRNA and protein
levels. (A) HeLa (left panel), KIS-1 (middle panel) and MCF-7 (right panel) were treated
with PKC inhibitor for 24 h. A3B mRNA expression levels were measured by qPCR. Bar
graphs indicate mean ± S.D. (B). KIS-1 cells were treated with PKC inhibitor at 0.1, 1.0
and 10 mM for 48 h and subjected to immunoblotting. (C) HeLa cells were transfected
with luciferase reporter construct that contains A3B promoter sequence (975 to þ44
from TSS) and treated with 1 ng/mL PMA ± 5 mM PKC inhibitor (GF109203X). Bar
Graphs indicate relative luciferase activities. (D) HeLa cells were transfected with A3B
luciferase reporter plasmid and expression vector for either empty vector, PKC WT
(wild type), K/R (kinase-deﬁcient mutant) or A/E (constitutive active mutant).
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expression 2 and 40 folds in HeLa and Jurkat cells, respectively. IFNa
treatment also induced 2 folds in HeLa cells, but no change in Jurkat
cells. TNFa did not induce A3B mRNA expression in either cell line.
More importantly, upregulation of A3B protein levels in response to
PMA stimulation were clearly detected in not only HeLa and Jurkat
cells, but also other cancer cell lines such as KIS-1, MCF7 and
Granta519 (Fig. 1D).3.2. PKC is responsible for A3B expression
Since PMA is a strong activator of PKC family kinases, we
examined the contribution of PKC activation on A3B expression.We
treated HeLa, KIS-1 and MCF7 cells with a speciﬁc PKC inhibitor,
GF109203X at 5 mM, and checked mRNA expression levels by qPCR.
In all cell lines tested, A3B levels were apparently decreased
(Fig. 2A). Immunoblotting analysis also demonstrated that PKC in-
hibitor downregulated A3B protein expression in a dose dependent
manner (Fig. 2B). To evaluate the A3B promoter activities under PKC
inhibitor treatment, we used ﬁreﬂy luciferase reporter constructs
containing nucleotides 975 to þ44 from TSS of the A3B promoter
region. HeLa cells were transfected with reporter plasmids and
treated with 1 ng/mL PMA in the presence or absence of PKC in-
hibitor. PKC inhibitor blocked PMA-induced luciferase activities
(Fig. 2C). We also tested whether exogenous PKC expression in-
duces A3B mRNA expression and found that only the constitutiveactive form of PKCq induced A3B (Fig. 2D). These results indicate
that PKC is responsible for A3B expression upon PMA stimulation.3.3. NF-kB pathway regulates A3B expression downstream of PKC
To identify pathways downstream of PKC required for A3B
expression, we used the JASPAR database [19] to identify putative
transcription factor binding sites in the A3B promoter region, and
found STAT3, JUN and NF-kB as candidates, known signaling mol-
ecules downstream of PKC (Fig. 3A). We checked A3B mRNA
expression using qPCR after treatment with inhibitors of MEK, JNK
and IKK, which are activated by PKC and are located upstream of
STAT3, JUN and NF-kB, respectively. Among these, only IKK inhib-
itor reduced A3B expression in HeLa, KIS-1 and MCF7 cells (Fig. 3B).
IKK inhibitor also reduced A3B protein levels in HeLa, KIS-1, MCF7,
and Granta519 cells (Fig. 3C). These results suggest that NF-kB is the
key transcriptional factor for A3B expression.
Fig. 3. IKK/NF-kB signaling pathway regulates A3B expression downstream of PKC. (A) Schematic representation of main transcription factor binding sites predicted by JASPAR
database (http://jasper.binf.ku.dk). (B) HeLa (left panel), KIS-1 (middle panel) and MCF7 (right panel) cells were treated with 10 mM IKK inhibitor (U0216), 10 mM MEK inhibitor
(SP600125) or 5 mM JNK inhibitor (BMS345541) for 24 h. A3B mRNA levels were measured by qPCR and normalized to DMSO treated control samples. Bar graphs indicate
mean ± S.D. (C) Cells were treated with IKK inhibitor at indicated concentrations for 24 h. Nuclear lysates were subject to immunoblotting.
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three NF-kB binding motifs of the A3B promoter
To evaluate NF-kB binding sites, we performed promoter assays
using ﬁreﬂy luciferase reporter constructs containing A3B promoter
regions (975 to þ44 from the TSS) or shorter promoters as
depicted in Fig. 4A. We transfected these plasmids into HeLa cells,
treated with PMA or DMSO as control, and measured luciferase
activity. PMA treatment induced about two folds higher luciferase
activity, but not when plasmids with a promoter shorter than 150
were co-transfected (Fig. 4A), suggesting that the A3B promoter
region which includes 235 to þ44 nucleotides from TSS is
important for A3B expression. The promoter region between 235
and þ44 includes four putative NF-kB binding sites, kB1, kB2, kB3
and kB4, as predicted by the JASPAR database (Figs. 3A and 4B). We
next tested the kB binding motif mutant reporters depicted in
Fig. 4B and found that mutants in each kB binding site, except for
kB1, showed impaired promoter activity and the triple mutant
completely lost its activity, suggesting that the 3 binding motifs,
kB2, kB3 and kB4, close to TSS are important for A3B expression
(Fig. 4B). To conﬁrm the binding of NF-kB to its motifs in the A3B
promoter, we employed electrophoretic mobility shift assay
(EMSA). HeLa cell nuclear extracts were incubated with labeled
DNA probes for four putative NF-kB binding sites with or without
unlabeled kB probe or control AP1 probe. Nuclear extracts with
probes kB2, kB3, and kB4 formed slow migrating bands, proof of
DNA-protein complex assembly (Fig. 4C), while those with kB1 did
not. PMA treatment resulted in an increase of these complexes. The
unlabeled speciﬁc competitor kB probe reduced the complex sig-
nals, while the non-speciﬁc competitor AP1 probe did not affect
those, suggesting that NF-kB speciﬁcally binds to kB binding motifs
2 to 4 (Fig. 4C). To identify the proteins bound to the sequences, we
performed supershift analysis using speciﬁc antibodies against p50,
p52, c-Rel, and p65. The supershift was detected with antibodies
against p50 and p65 on the kB2 probe, while with antibodies
against c-Rel and p65 on the kB3 and kB4 probes (Fig. 4D). Finally,
we transduced speciﬁc lentiviral shRNA to knock down p65 in HeLa
cells and checked kB promoter activity. Upon PMA treatment, p65knockdown abrogated A3B promoter activity (Fig. 4E). We further
transduced p65 shRNA in KIS-1 cells, which highly express A3B, and
found that A3B protein level was reduced post transduction
(Fig. 4F). These results suggest that PKC mediated classical NF-kB
pathway is important for A3B expression in cancer cell lines.
4. Discussion
In this study, we showed that PKC and the downstream classical
NF-kB pathway play a crucial role in the transcriptional regulation
of A3B. We demonstrated that A3B is aberrantly expressed in a
variety of cancer cells and that the PKC/IKK pathway induces
upregulation of A3B expression at both mRNA and protein levels.
We next showed that classical NF-kB pathway molecules bind to
the A3B promoter region before the TSS, which is essential for A3B
expression upon PMA stimulation. These ﬁndings clearly show that
NF-kB activation leads to aberrant expression of the intrinsic DNA
mutator, A3B.
NF-kB activation is frequently observed in most solid tumors
and hematologic malignancies and is associated with worse prog-
nosis [20]. Activating mutations in NF-kB genes were ﬁrst found in
B-cell lymphoid malignancies, but are rare in solid tumors [12].
Instead, mutations of upstream signaling molecules, such as Ras,
EGFR, PDGF, HER2, lead to constitutive activation of NF-kB in solid
tumors [21]. Various cytokine stimuli also contribute to NF-kB
activation in the tumor microenvironment [21]. Both classical and
alternative pathways are activated, to various extents, in a wide
variety of cancers [21,22]. Although a recent report by Leonard et al.
showed that the alternative NF-kB pathway induces A3B [16], our
data support that the classical pathway is also important for A3B
expression. This discrepancy might originate from the experi-
mental procedures used in the two studies. It is also possible that
the different cancer cells used in these studies might overexpress
A3B through different pathways. Further studies are necessary to
clarify the roles of classical and alternative pathways in A3B
expression.
Recent reports showed that viral proteins such as human pap-
illoma virus (HPV) E6, E7, and polyoma virus large T antigen (TAg),
Fig. 4. Classical NF-kB pathway is important for A3B expression. (A) HeLa cells were transfected with luciferase reporter plasmid with A3B promoter or truncated form and
treated with or without 1 ng/mL PMA for 12 h. Lucifease activities were measured by a luminometer. White bar graphs indicate luciferase activity without PMA and grey bar
indicates that with PMA treatment (left panel). Bar graphs represent fold induction by PMA treatment and indicate mean ± S.D. (right panel) (B) Schematic representation of
luciferase reporter construct with truncated form of A3B promoter region (235 to þ44 from TSS). White boxes indicate putative NF-kB binding sites. X indicates mutated NF-kB
binding sites. HeLa cells were transfected with these constructs followed by PMA treatment for 24 h. White bar graphs indicate luciferase activity without PMA and grey bar
indicates that with PMA treatment. (C) EMSA assay using each NF-kB binding site sequence probe depicted in (B). HeLa cell extracts were incubated with unlabeled NF-kB sequence
or AP1 binding site sequence used as competitor DNA. Mixtures were separated by gel electrophoresis and probed with each DIG labeled NF-kB sequence. (D) Speciﬁc antibodies
against indicated NF-kB family proteins were used for super shift assay. Asterisk indicates DNA-transcription factor-antibody complex. (E) HeLa cells were transduced with lentiviral
shRNA for NF-kB p65 or non-target control ﬁve days before transfection and transfected with luciferase reporter constructs followed by PMA treatment. (F) KIS-1 cells were
transduced with lentiviral shRNA for NF-kB p65 or non-target control. Five days later cells were subjected to immunoblotting using indicated antibodies.
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risk HPV type 16 is known to activate the NF-kB pathway [25], viral
infection and viral proteins might also induce A3B expression
through NF-kB activation. On the other hand, others reported that
A3B is induced by IFN in hepatocytes [26]. Various virus-related
molecules have been identiﬁed to inﬂuence A3B expression and
all the related pathways have yet to be completely elucidated.
Inhibition of NF-kB pathway using PKC and/or IKK inhibitors is a
possible strategy to suppress A3B expression and combinational
use of these inhibitors might be useful to reduce tumor progression
and metastasis driven by A3B-mediated mutations during
chemotherapy.
In conclusion, we provide here evidence that the PKC/IKK/NFkBsignaling pathway induces aberrant expression of A3B in various
cancer cells, which might result in accumulation of somatic mu-
tations and promotion of genetic diversity in various types of
cancer. Understanding the precise regulation mechanisms of A3B
expression and targeting the PKC/IKK/NFkB pathwaymight provide
a new strategy for preventing cancer progression, metastasis and
acquisition of drug resistance.Acknowledgements
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